Deep vein thrombosis

Deep vein thrombosis (DVT) is the formation of a blood clot in a deep vein, most commonly the legs.[2][lower-alpha 1] Symptoms may include pain, swelling, redness, or warmth of the affected area.[2] About half of cases have no symptoms.[2] Complications may include pulmonary embolism, as a result of detachment of a clot which travels to the lungs, and post-thrombotic syndrome.[2][3]

Deep vein thrombosis
Other namesDeep venous thrombosis
Economy-class syndrome[1]
DVT in the right leg with swelling and redness
SymptomsPain, swelling, redness, or warmth of the affected area[2]
ComplicationsPulmonary embolism, post-thrombotic syndrome[2][3]
Risk factorsRecent surgery, cancer, trauma, lack of movement, obesity, smoking, hormonal birth control, pregnancy and the period following birth, antiphospholipid syndrome, certain genetic conditions[2][3]
Diagnostic methodUltrasound[2]
Differential diagnosisBaker's cyst, cellulitis, hematoma, varicose veins[4]
PreventionFrequent walking, calf exercises, aspirin, anticoagulants (blood thinners), graduated compression stockings, intermittent pneumatic compression[5]
TreatmentAnticoagulation, graduated compression stockings[2]
MedicationLow-molecular-weight heparin, warfarin, direct oral anticoagulant[3][5]
Frequency1 in 1,000 people per year[6]

Risk factors include recent surgery, cancer, trauma, lack of movement, obesity, smoking, hormonal birth control, pregnancy and the period following birth, antiphospholipid syndrome, and certain genetic conditions.[2][3] Genetic factors include deficiencies of antithrombin, protein C, and protein S, and factor V Leiden mutation.[3] The underlying mechanism typically involves some combination of decreased blood flow rate, increased tendency to clot, and injury to the blood vessel wall.[2]

Individuals suspected of having DVT may be assessed using a clinical prediction rule such as the Wells score.[3][4] A D-dimer test may also be used to assist with excluding the diagnosis or to signal a need for further testing.[2] Diagnosis is most commonly confirmed by ultrasound of the suspected veins.[2] Together, DVT and pulmonary embolism are known as venous thromboembolism (VTE).[2]

Anticoagulation (blood thinners) is the standard treatment.[2] Typical medications include low-molecular-weight heparin, warfarin, or a direct oral anticoagulant.[3] Wearing graduated compression stockings may reduce the risk of post-thrombotic syndrome.[5] Preventive efforts following surgery may include early and frequent walking, calf exercises, aspirin, anticoagulants, graduated compression stockings, or intermittent pneumatic compression.[5] The rate of DVTs increases from childhood to old age; in adulthood, about one in 1000 adults are affected per year.[6] About 5% of people are affected by a VTE at some point in time.[4]

Signs and symptoms

Illustration depicting a deep vein thrombosis

Common signs and symptoms of DVT include pain or tenderness, swelling, warmth, redness or discoloration, and distention of surface veins, although about half of those with the condition have no symptoms.[7] Signs and symptoms alone are not sufficiently sensitive or specific to make a diagnosis, but when considered in conjunction with known risk factors, can help determine the likelihood of DVT.[8] In most suspected cases, DVT is ruled out after evaluation,[9] and symptoms are more often due to other causes, such as cellulitis, Baker's cyst, musculoskeletal injury, or lymphedema.[10] Other differential diagnoses include hematoma, tumors, venous or arterial aneurysms, and connective tissue disorders.[11]

Phlegmasia alba dolens and phlegmasia cerulea dolens occur when a DVT is very large and causes significant obstruction of the veins (complete or near-complete occlusion). In the former, the affected leg is white and painful as the congestion is so severe that the arterial blood supply is reduced. In the latter, the arterial supply is reduced to the point that there is a blue tinge and venous gangrene may develop, generally with severe pain. Surgery may be required in this setting.[12][13]


The incision for a completed knee replacement surgery, a procedure that can predispose people to a DVT

The three factors of Virchow's triadvenous stasis, hypercoagulability, and changes in the endothelial blood vessel lining (such as physical damage or endothelial activation)—contribute to DVT and are used to explain its formation.[14][15] Other related causes include activation of immune system components, the state of microparticles in the blood, the concentration of oxygen, and possible platelet activation.[16] Various risk factors contribute to DVT, though many at high risk never develop it.[17]

Acquired risk factors include the strong risk factor of older age,[15][17] which alters blood composition to favor clotting. Other important acquired risk factors include major surgery and trauma, both of which may increase the risk because of tissue factor from outside the vascular system entering the blood.[14] In orthopedic surgery, venous stasis may be temporarily provoked by a cessation of blood flow as part of the procedure.[16] Cancer can grow in and around veins, causing venous stasis, and can also stimulate increased levels of tissue factor. Pregnancy causes blood to favor clotting, and in the postpartum, placental tearing releases substances that favor clotting. Oral contraceptives[lower-alpha 2] and hormonal replacement therapy increase the risk through a variety of mechanisms, including altered blood coagulation protein levels and reduced fibrinolysis.[16]

The disease term venous thromboembolism (VTE) includes the development of either DVT or pulmonary embolism (PE).[20][21] Genetic factors that increase the risk of VTE include deficiencies of three proteins that normally prevent blood from clotting—protein C, protein S, and antithrombin—in addition to non-O blood type and mutations in the factor V and prothrombin genes. Deficiencies in antithrombin, protein C, and protein S are rare but strong, or moderately strong, risk factors.[14][16] These three thrombophilia[lower-alpha 3] increase the risk of VTE by about 10 times.[22] Factor V Leiden, which makes factor V resistant to inactivation by activated protein C,[24] and the genetic variant prothrombin G20210A, which causes increased prothrombin levels, are predominantly expressed in Caucasians.[14][lower-alpha 4] They moderately increase risk for VTE, by three to eight times for factor V Leiden and two to three times for prothrombin G20210A.[22][25] Having a non-O blood type roughly doubles VTE risk.[16] Non-O blood type is common in all races, making it an important risk factor.[26] Individuals without O blood type have higher blood levels of von Willebrand factor and factor VIII than those with O blood type, increasing the likelihood of clotting.[26]

Some risk factors influence the location of DVT within the body. In isolated distal DVT, the profile of risk factors appears distinct from proximal DVT. Transient factors, such as surgery and immobilization, appear to dominate, whereas thrombophilias and age do not seem to increase risk.[27] In upper-extremity DVT, the most important risk factor is having a central venous catheter, and thoracic outlet syndrome also increases risk.[20]

Risk factors

The femoral vein (in the thigh), the iliac veins (in the pelvis), and the inferior vena cava (in the abdomen) are places of potential DVT extension.





The coagulation system, often described as a "cascade", consists of a group of proteins that interact to form a blood clot. DVT risk is increased by abnormalities in the cascade. The regulators, antithrombin (ᾳTHR) and activated protein C (APC) are shown in green above the blood's clotting factors they affect.

DVT often develops in the calf veins and "grows" in the direction of venous flow, towards the heart.[38] When DVT does not grow, it can be cleared naturally and dissolved into the blood (fibrinolysis).[39] Veins in the calf or thigh are most commonly affected,[40] including the femoral vein, the popliteal vein, and the iliofemoral vein (as with May–Thurner syndrome). Extensive lower-extremity DVT can reach into the iliac vein of the pelvis or the inferior vena cava.[41] Occasionally the veins of the arm are affected, as after central venous catheter placement and with the rare Paget–Schrötter disease.[30]

The mechanism behind arterial thrombosis, such as with heart attacks, is more established than the steps that cause venous thrombosis.[42] With arterial thrombosis, blood vessel wall damage is required, as it initiates coagulation,[42] but clotting in the veins mostly occurs without any such damage.[14] The beginning of venous thrombosis is thought to be caused by tissue factor, which leads to conversion of prothrombin to thrombin, followed by fibrin deposition.[15] Red blood cells and fibrin are the main components of venous thrombi,[14] and the fibrin appears to attach to the blood vessel wall lining (endothelium), a surface that normally acts to prevent clotting.[42] Platelets and white blood cells are also components. Platelets are not as prominent in venous clots as they are in arterial ones, but they may play a role.[16] Inflammation is associated with VTE,[lower-alpha 6] and white blood cells play a role in the formation and resolution of venous clots.[39]

Often, DVT begins in the valves of veins.[39] The blood flow pattern in the valves can cause low oxygen concentrations in the blood (hypoxemia) of a valve sinus. Hypoxemia, which is worsened by venous stasis, activates pathways—ones that include hypoxia-inducible factor-1 and early-growth-response protein 1. Hypoxemia also results in the production of reactive oxygen species, which can activate these pathways, as well as nuclear factor-κB, which regulates hypoxia-inducible factor-1 transcription.[15] Hypoxia-inducible factor-1 and early-growth-response protein 1 contribute to monocyte association with endothelial proteins, such as P-selectin, prompting monocytes to release tissue factor-filled microvesicles, which presumably begin clotting after binding to the endothelial surface.[15]

Deep vein thrombosis occurs in the upper extremities in about 4–10% of cases, generally in people with severe underlying diseases, especially cancer.[43]


DVT diagnosis requires the use of imaging devices such as ultrasound. Clinical assessments, which predict DVT likelihood, can help determine if a D-dimer test is useful. In those not highly likely to have DVT, a normal D-dimer result[lower-alpha 7] can rule out a diagnosis. A ruptured baker's cyst can mimic the presentation of a deep vein thrombosis.


Provoked DVTs occur in association with acquired risk factors, such as surgery, oral contraceptives, trauma, immobility, obesity, or cancer; cases without acquired states are called unprovoked or idiopathic.[45] Unprovoked VTE may indicate an underlying cancer and testing for cancer in people with unprovoked VTE may lead to an earlier cancer diagnosis at an earlier stage of the disease.[46] Acute DVT is characterized by pain and swelling[47] and is usually occlusive,[8] which means that it obstructs blood flow, whereas non-occlusive DVT is less symptomatic.[13] The label "chronic" has been applied to symptomatic DVT that persists longer than 10 to 14 days.[48] DVT that has no symptoms, but is found only by screening, is labeled asymptomatic or incidental.[49][50]

DVT in the legs is proximal (or iliofemoral[51]) when above the knee and distal (or calf) when below the knee.[52][53] DVT below the popliteal vein, a proximal vein behind the knee, is classified as distal[8] and has limited clinical significance compared to proximal DVT.[54] An initial episode of DVT is called incident and any subsequent DVT is termed recurrent.[55][56] Bilateral DVT refers to clots in both legs while unilateral means that only a single leg is affected.[57]


Swelling in the leg from fluid (edema) can result in "pitting" after pressure is applied. (This person did not have DVT.)

In those with suspected DVT, a clinical assessment of probability can be useful to determine which tests to perform.[58][59] The most studied clinical prediction rule is the Wells score.[9][60]

Wells score or criteria: (possible score −2 to 9)

  1. Active cancer (treatment within last 6 months or palliative): +1 point
  2. Calf swelling ≥ 3 cm compared to asymptomatic calf (measured 10 cm below tibial tuberosity): +1 point
  3. Swollen unilateral superficial veins (non-varicose, in symptomatic leg): +1 point
  4. Unilateral pitting edema (in symptomatic leg): +1 point
  5. Previous documented DVT: +1 point
  6. Swelling of entire leg: +1 point
  7. Localized tenderness along the deep venous system: +1 point
  8. Paralysis, paresis, or recent cast immobilization of lower extremities: +1 point
  9. Recently bedridden ≥ 3 days, or major surgery requiring regional or general anesthetic in the past 12 weeks: +1 point
  10. Alternative diagnosis at least as likely: −2 points[10]

Those with Wells scores of two or more have a 28% chance of having DVT, those with a lower score have 6% probability. Alternatively, Wells scores can be categorized as high if greater than two, moderate if one or two, and low if less than one, with likelihoods of 53%, 17%, and 5%, respectively.[9][10]


D-dimers are a fibrin degradation product, and an elevated level can result from plasmin dissolving a clot—or other conditions.[44] Hospitalized patients often have elevated levels for multiple reasons.[9][61] When individuals are at a high-probability of having DVT, diagnostic imaging is preferred to a D-dimer test.[59][62] For those with a low or moderate probability of DVT, a D-dimer level might be obtained, which excludes a diagnosis if results are normal.[44] An elevated level requires further investigation with diagnostic imaging to confirm or exclude the diagnosis.[63][64]

For a suspected first leg DVT in a low-probability situation, the American College of Chest Physicians recommends testing either D-dimer levels with moderate or high sensitivity or compression ultrasound of the proximal veins. These options are suggested over whole-leg ultrasound, and D-dimer testing is the suggested preference overall.[63] The UK National Institute for Health and Care Excellence (NICE) recommends D-dimer testing prior to proximal vein ultrasound.[59]

For a suspected first leg DVT in a moderate-probability scenario, a high-sensitivity D-dimer is suggested as a recommended option over ultrasound imaging, with both whole-leg and compression ultrasound possible.[64] The NICE guideline uses a two-point Wells score and does not refer to a moderate probability group.[59]


Imaging tests of the veins are used in the diagnosis of DVT, most commonly either proximal compression ultrasound or whole-leg ultrasound. Each technique has drawbacks: a single proximal scan may miss a distal DVT, while whole-leg scanning can lead to distal DVT overtreatment.[9] Doppler ultrasound,[65] CT scan venography, MRI venography, or MRI of the thrombus are also possibilities.[9][63]

Ultrasonography for suspected deep vein thrombosis has a sensitivity of 97% in detecting DVTs of the proximal legs.[66]

The gold standard for judging imaging methods is contrast venography, which involves injecting a peripheral vein of the affected limb with a contrast agent and taking X-rays, to reveal whether the venous supply has been obstructed. Because of its cost, invasiveness, availability, and other limitations, this test is rarely performed.[9] In one study, it found a DVT in an additional 20% of patients with pulmonary embolism where an ultrasonography was negative.[67]


The American College of Chest Physicians-suggested graduated compression stockings for at-risk travelers and some hospital patients

Depending upon the risk for DVT, different preventive measures are recommended. Walking and calf exercises reduce venous stasis because leg muscle contractions compress the veins and pump blood up towards the heart.[68] In immobile individuals, physical compression methods improve blood flow. Anticoagulation, which increases the risk of bleeding, might be used in high-risk scenarios. The risk of major bleeding with long-term anticoagulation is about 3% per year,[22] and the point where annual VTE risk is thought to warrant long-term anticoagulation is estimated to be between 3 and 9%.[69] Usually, only when individuals exceed a 9% annual VTE risk is long-term anticoagulation a common consideration.[69] Antithrombin deficiency, a strong or moderately strong risk factor, carries an annual risk of VTE of only 0.8–1.5%;[22] as such, asymptomatic individuals with thrombophilia do not warrant long-term anticoagulation.[70]

Aside from anticoagulation, the antiplatelet drug aspirin might be used in some people following orthopedic surgery [71] and in those with a previous VTE.[72] Statins might decrease the risk for people who are otherwise healthy, but the evidence is not clear.[73] Following the completion of warfarin, long-term aspirin is useful to prevent re occurrence.[74]


In 2011, the American College of Physicians (ACP) issued a clinical practice guideline making three strong recommendations based on moderate-quality evidence: that hospitalized patients be assessed for their risk of thromboembolism and bleeding before prophylaxis is started; that heparin or a related drug be used if potential benefits are thought to outweigh potential harms; and that graduated compression stockings not be used. The ACP also drew attention to a lack of support for any performance measures encouraging physicians to apply universal prophylaxis without regard to the risks.[21][75]

A 2014 Cochrane review found that using heparin in medical patients did not change the risk of death or pulmonary embolism.[76] While its use decreased people's risks of DVTs, it also increased people's risks of major bleeding.[76] The review thus recommended the need to balance risks and benefits.[76]

The 2012 ACCP guidelines for nonsurgical patients[77][lower-alpha 8] recommend anticoagulation for the acutely ill in cases of elevated risk when neither bleeding nor a high risk of bleeding exists.[78] Mechanical prophylaxis is suggested when risks for bleeding and thrombosis are elevated.[79] For the critically ill, either pharmacological or mechanical prophylaxis is suggested depending upon the risk.[80] Heparin is suggested in outpatients with cancer who have solid tumors and additional risk factors for VTE—listed as "previous venous thrombosis, immobilization, hormonal therapy, angiogenesis inhibitors, thalidomide, and lenalidomide"—and a low risk of bleeding.[81]

After surgery

Major orthopedic surgery—total hip replacement, total knee replacement, or hip fracture surgery—has a high risk of causing VTE.[82] If prophylaxis is not used after these surgeries, symptomatic VTE has about a 4% chance of developing within 35 days.[83] Options for VTE prevention in people following nonorthopedic surgery include early walking, mechanical prophylaxis (intermittent pneumatic compression or graduated compression stockings), and drugs (low-molecular-weight heparin and low-dose-unfractionated heparin) depending upon the risk of VTE, risk of major bleeding, and person's preferences.[84] Following major orthopedic surgery, the ACCP recommends treatment with drugs that reduce the risk of clots (such as fondaparinux and aspirin) with low-molecular-weight heparin (LMWH) suggested as a preference.[83] Intermittent pneumatic compression is also an option.[83][85] Graduated compression stockings are effective after both general and orthopedic surgery.[86]


Warfarin, a common VKA, is suggested only after childbirth in some at-risk women.

The risk of VTE is increased in pregnancy by about five times[22][87] because of a more hypercoagulable state, a likely adaptation against fatal postpartum hemorrhage.[28] Additionally, pregnant women with genetic risk factors are subject to a roughly three to 30 times increased risk for VTE.[88] Preventative treatments for pregnancy-related VTE in hypercoagulable women were suggested by the ACCP. Homozygous carriers of factor V Leiden or prothrombin G20210A with a family history of VTE were suggested for antepartum LMWH and either LMWH or a vitamin K antagonist (VKA) for the six weeks following childbirth. Those with another thrombophilia and a family history but no previous VTE were suggested for watchful waiting during pregnancy and LMWH or—for those without protein C or S deficiency—a VKA. Homozygous carriers of factor V Leiden or prothrombin G20210A with no personal or family history of VTE were suggested for watchful waiting during pregnancy and LMWH or a VKA for six weeks after childbirth. Those with another thrombophilia but no family or personal history of VTE were suggested for watchful waiting only.[89] Warfarin, a common VKA, can cause harm to the fetus and is not used for VTE prevention during pregnancy.[88][90]


The 2012 ACCP guidelines offered weak recommendations. For at-risk long-haul travelers—those with "previous VTE, recent surgery or trauma, active malignancy, pregnancy, estrogen use, advanced age, limited mobility, severe obesity, or known thrombophilic disorder"—suggestions included calf exercises, frequent walking, and aisle seating in airplanes to ease walking.[91][1] The use of graduated compression stockings that fit below the knee and give 15–30 mm Hg of pressure to the ankle was suggested, while aspirin or anticoagulants were not.[92] Compression stockings have sharply reduced the levels of asymptomatic DVT in airline passengers, but the effect on symptomatic VTE is unknown, as none of the individuals studied developed symptomatic VTE.[93]



Structural representations of the backbone of heparins (left), which vary in the size of their chain, and the synthetic pentasaccaride (five-sugar) fondaparinux (right)

Anticoagulation, which prevents further coagulation, but does not act directly on existing clots, is the standard treatment for DVT.[94][lower-alpha 9] Balancing risk vs. benefit is important in determining the duration of anticoagulation, and three months is generally the standard length of treatment.[59] In those with an annual risk of VTE in excess of 9%, as after an unprovoked episode, extended anticoagulation is a possibility.[69] Those who finish VKA treatment after idiopathic VTE with an elevated D-dimer level show an increased risk of recurrent VTE (about 9% vs about 4% for normal results), and this result might be used in clinical decision-making.[96] Thrombophilia test results rarely play a role in the length of treatment.[33] Two forms of direct oral anticoagulants (DOACs) have been developed: oral direct thrombin inhibitors (DTI) and oral factor Xa inhibitors, which may be an effective and safe alternative to warfarin for acute DVT.[97]

For acute cases in the leg, the ACCP recommended a parenteral anticoagulant (such as LMWH, fondaparinux, or unfractionated heparin) for at least five days[lower-alpha 10] and a VKA, the oral anticoagulant, the same day. LMWH and fondaparinux are suggested over unfractionated heparin, but both are retained in those with compromised kidney function, unlike unfractionated heparin.[99][100] The VKA is generally taken for a minimum of three months[101] to maintain an international normalized ratio of 2.0–3.0, with 2.5 as the target.[102][103] The benefit of taking a VKA declines as the duration of treatment extends,[104] and the risk of bleeding increases with age.[20]

The ACCP recommended treatment for three months in those with proximal DVT provoked by surgery.[105] A three-month course is also recommended for those with proximal DVT provoked by a transient risk factor, and three months is suggested over lengthened treatment when bleeding risk is low to moderate.[106] Unprovoked DVT patients should have at least three months of anticoagulation and be considered for extended treatment.[107] Those whose first VTE is an unprovoked proximal DVT are suggested for anticoagulation longer than three months unless there is a high risk of bleeding.[108] In that case, three months is sufficient.[109] Those with a second unprovoked VTE are recommended for extended treatment when bleeding risk is low, suggested for extended treatment when bleeding risk is moderate,[110] and suggested for three months of anticoagulation in high-risk scenarios.[111]

Stockings, walking, and repeat imaging

The ACCP recommended initial home treatment instead of hospital treatment for those with acute leg DVT. This applies as long as individuals feel ready for it, and those with severe leg symptoms or comorbidities would not qualify. An appropriate home environment is expected: one that can provide a quick return to the hospital if necessary, support from family or friends, and phone access.[112]

In addition to anticoagulation, the ACCP suggested graduated compression stockings—which apply higher pressure (30–40 mm Hg) at the ankles and a lower pressure around the knees[99]—for those with symptomatic DVT.[113] Use should begin as soon as possible after anticoagulation.[99] Evidence, however, does not support that these stockings reduce the risk of post-thrombotic syndrome nor do they indicate a reduction in recurrent VTE.[114] Use is suggested for two years, though inconvenience and discomfort can reduce compliance.[113] Walking is also suggested for those without severe pain or edema.[115]

Unless a person has medical problems preventing movement, after a person starts anti-coagulation therapy, bed rest should not be used to treat acute deep vein thrombosis.[116] There are clinical benefits associated with walking and no evidence that walking is harmful, but people with DVT are harmed by bed rest except when it is medically necessary.[116]

Instead of anticoagulation, a follow-up imaging test (typically ultrasound) about one-week post-diagnosis is an option for those with an acute isolated distal DVT without a high risk for extension; if the clot does not grow, the ACCP does not recommend anticoagulation.[99][117] This technique can benefit those at a high risk for bleeding. Patients may choose anticoagulation over serial imaging, however, to avoid the inconvenience of another scan if concerns about the risk of bleeding are insignificant.[117] When applied to symptomatic patients with a negative initial ultrasound result, serial testing is inefficient and not cost effective.[8]

IVC filters, thrombolysis, and thrombectomy

An IVC filter

Inferior vena cava filters (IVC filters) are used on the presumption that they reduce PE, although their effectiveness and safety profile are not well established.[118] In general, they are only recommended in some high-risk scenarios.[118] The ACCP recommended them for those with a contraindication to anticoagulant treatment but not in addition to anticoagulation, unless an individual with an IVC filter but without a risk for bleeding develops acute proximal DVT. In this case, both anticoagulation and an IVC filter are suggested.[119] NICE recommends caval filters in settings where someone with an acute proximal DVT or PE cannot receive anticoagulation, and that the filter is removed when anticoagulation can be safely started.[59] While IVC filters themselves are associated with a long-term risk of DVT,[118] they are not reason enough to maintain extended anticoagulation.[120]

Thrombolysis is the administration of an enzyme (intravenous or directly into the affected vein through a catheter), which acts to enzymatically break up clots. This may reduce the risk of post-thrombotic syndrome by a third, and possibly reduce the risk of leg ulcers, but is associated with a small increased risk of bleeding.[121] The ACCP currently suggests anticoagulation rather than thrombolysis, but patients may choose thrombolysis if prevention of post-thrombotic syndrome outweighs concerns over the complexity, bleeding risk, and cost of the procedure.[122] NICE recommends that thrombolysis is considered in those who have had symptoms for less than two weeks, are normally well, have a good life expectancy and a low risk of bleeding.[59]

A mechanical thrombectomy device can remove venous clots, although the ACCP considers it an option only when the following conditions apply: "iliofemoral DVT, symptoms for < 7 days (criterion used in the single randomized trial), good functional status, life expectancy of ≥ 1 year, and both resources and expertise are available."[99] Anticoagulation alone is suggested over thrombectomy.[123]


The most frequent complication of proximal DVT is post-thrombotic syndrome,[124] which is caused by a reduction in the return of venous blood to the heart.[18] Some symptoms of post-thrombotic syndrome are pain, edema, paresthesia, and in severe cases, leg ulcers. An estimated 20–50% of those with DVT will develop it, and 5–10% will develop the severe form.[124] PE is the most serious complication of proximal DVT, and the risk of PE is higher when clots are present in the thigh and pelvis.[118] Distal DVT itself is hardly if ever associated with post-thrombotic syndrome or PE.[9] Untreated lower extremity DVT has a 3% PE-related mortality rate, while deaths associated with upper extremity DVT are extremely rare.[29] The presence of a remaining thrombus after a DVT occurs in a minority of people, and it increases the risk of recurrence, though to a lesser extent than an elevated D-dimer.[18] In the 10 years following a DVT, approximately a third of individuals will have a recurrent episode.[125]


About 1 in 1000 adults per year has DVT,[126] but as of 2011, available data are dominated by North American and European populations.[6] VTE is rare in children, with an incidence of about 1 in 100,000 a year. From childhood to old age, incidence increases by a factor of about 1000, with almost 1% of the elderly experiencing VTE yearly.[127] During pregnancy and after childbirth, acute VTE occurs about once per 1000 deliveries.[88] After surgery with preventative treatment, VTE develops in about 10 of 1000 people after total or partial knee replacement, and in about 5 of 1000 after total or partial hip replacement.[128] About 300,000–600,000 Americans develop VTE each year, with about 60,000–100,000 deaths attributable to PE.[125] In England, an estimated 25,000 a year die from hospital-related VTE.[129] For unclear reasons, people of Asian descent have a lower VTE risk than whites.[6]

In North American and European populations, around 4–8% of people have a thrombophilia,[22] most commonly factor V leiden and prothrombin G20210A. For populations in China, Japan, and Thailand, deficiences in protein S, protein C, and antithrombin predominate.[130] Non-O blood type is present in around 50% of the general population and varies with ethnicity, and it is present in about 70% of those with VTE.[26][131] Altogether, global data is incomplete.[132]


Rudolf Virchow

The earliest case of DVT was described by Sushruta in his book Sushruta Samhita around 600–900 BC.[133] Another documented case is thought to have occurred in the 13th century, in the leg of a 20-year-old male.[17] At some point, the increased incidence of DVT in women after childbirth was noticed, and in the late 1700s, a public health recommendation was issued to encourage women to breastfeed as a means to prevent this phenomenon; the DVT was called "milk leg", as it was thought to result from milk building up in the leg.[134]

In 1856, German physician and pathologist Rudolf Virchow published what is referred to as Virchow's triad, the three major causes of thrombosis.[17][134] The triad provides the theoretical framework for the current explanation of venous thrombosis,[17] although it was focused on the effect of a foreign body in the venous system and the conditions required for clot propagation.[135]

Multiple pharmacological therapies for DVT were introduced in the 20th century: oral anticoagulants in the 1940s, subcutaneous LDUH in 1962 and subcutaneous LMWH in 1982.[136] Diagnoses were commonly performed by impedance plethysmography in the 1970s and 1980s, but the use of Doppler ultrasound techniques, with their increased sensitivity and specificity, largely superseded this method.[137]


Initial DVT costs for an average hospitalized patient in the U.S. are around $7,700–$10,800.[138] VTE follow-up costs at three months, six months, and a year are about $5,000, $10,000, and $33,000 respectively; in Europe, the three and six-month figures are about €1,800 and €3,200.[139] Post-thrombotic syndrome is a significant contributor to DVT follow-up costs.[138] Annual DVT costs in the U.S. are an estimated $5 billion[140] or in excess of $8 billion,[141][142] and the average annual cost per treated individual is thought to be about $20,000.[141] As an example, if 300,000 symptomatic DVT patients were treated at costs averaging $20,000 annually, that would cost $6 billion a year.

Research directions

As of 2011, three large randomized controlled trials—the Norwegian CaVent trial, the North American ATTRACT trial, and the Dutch CAVA trial—are studying the effectiveness and safety of catheter-directed thrombolysis.[102] In 2012, two studies[143][144] found a clinical benefit in taking aspirin to prevent recurrent VTE.[72]


  1. Thrombosis associated with the abdominal organs (viscera)—such as portal vein thrombosis, renal vein thrombosis, and Budd–Chiari syndrome—are separate diseases excluded from the scope of this definition.
  2. Third-generation combined oral contraceptives (COCs) have an approximate two to three times higher risk than second-generation COCs.[18] Progestogen-only pill use is not associated with increased VTE risk.[19]
  3. The term 'thrombophilia' as used here applies to the five inherited abnormalities of antithrombin, protein C, protein S, factor V, and prothrombin, as is done elsewhere.[22][23]
  4. Factor V Leiden and prothrombin G20210A are present in about 3–5% and 1–3%, respectively, of people of European descent.[22]
  5. Factor V Leiden increases the risk of DVT more than it does for PE, a phenomenon referred to as the factor V Leiden paradox.[36]
  6. VTE might cause the observed inflammation.[16]
  7. An elevated level is greater than 250 ng/mL D-dimer units (DDU) or greater than 0.5 μg/mL fibrinogen equivalent units (FEU).[44] A normal level is below these values.
  8. Page e197S of Kahn et al.[77] specifies that the guideline does not apply to those with "trauma and spinal cord injury" nor does it apply to those "with ischemic and hemorrhagic stroke."
  9. Evidence for anticoagulation comes from studies other than definitive randomized controlled trials that demonstrate efficacy and safety for anticoagulation vs. placebo or using NSAIDs.[95]
  10. The international normalized ratio should be ≥ 2.0 for 24 hours minimum,[98] but if the ratio is > 3.0, then the parenteral anticoagulant is not needed for five days.[99]


  1. "New DVT guidelines: No evidence to support "economy-class syndrome"; oral contraceptives, sitting in a window seat, advanced age, and pregnancy increase DVT risk in long-distance travelers". American College of Chest Physicians. 7 February 2012. Archived from the original on 3 June 2016. Retrieved 10 February 2012.
  2. "Deep Vein Thrombosis". NHLBI, NIH. Archived from the original on 14 December 2017. Retrieved 14 December 2017.
  3. "Deep Venous Thrombosis (DVT)". Merck Manuals Professional Edition. July 2016. Archived from the original on 5 November 2017. Retrieved 15 December 2017.
  4. Ferri, Fred F. (2017). Ferri's Clinical Advisor 2018 E-Book: 5 Books in 1. Elsevier Health Sciences. p. 357. ISBN 9780323529570. Archived from the original on 15 December 2017.
  5. "Deep Venous Thrombosis Prevention – Cardiovascular Disorders – Merck Manuals Professional Edition". Merck Manuals Professional Edition. July 2016. Archived from the original on 18 September 2017. Retrieved 15 December 2017.
  6. Zakai NA, McClure LA (October 2011). "Racial differences in venous thromboembolism". Journal of Thrombosis and Haemostasis. 9 (10): 1877–82. doi:10.1111/j.1538-7836.2011.04443.x. PMID 21797965.
  7. "What are the signs and symptoms of deep vein thrombosis?". National Heart, Lung, and Blood Institute. 28 October 2011. Archived from the original on 18 April 2012. Retrieved 15 April 2012.
  8. Scarvelis D, Wells PS (October 2006). "Diagnosis and treatment of deep-vein thrombosis". CMAJ. 175 (9): 1087–92. doi:10.1503/cmaj.060366. PMC 1609160. PMID 17060659.
    Scarvelis D, Wells PS (October 2006). "Diagnosis and treatment of deep-vein thrombosis". CMAJ. 175 (9): 1087–92. doi:10.1503/cmaj.071550. PMC 2072980. PMID 17060659.
  9. Bates SM, Jaeschke R, Stevens SM, Goodacre S, Wells PS, Stevenson MD, et al. (February 2012). "Diagnosis of DVT: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines". Chest. 141 (2 Suppl): e351S–e418S. doi:10.1378/chest.11-2299. PMC 3278048. PMID 22315267.
  10. Hargett CW, Tapson VF (February 2008). "Clinical probability and D-dimer testing: how should we use them in clinical practice?". Seminars in Respiratory and Critical Care Medicine. 29 (1): 15–24. doi:10.1055/s-2008-1047559. PMID 18302083.
  11. Arumilli BR, Lenin Babu V, Paul AS (January 2008). "Painful swollen leg--think beyond deep vein thrombosis or Baker's cyst". World Journal of Surgical Oncology. 6: 6. doi:10.1186/1477-7819-6-6. PMC 2244628. PMID 18205917.
  12. Chinsakchai K, Ten Duis K, Moll FL, de Borst GJ (January 2011). "Trends in management of phlegmasia cerulea dolens". Vascular and Endovascular Surgery. 45 (1): 5–14. doi:10.1177/1538574410388309. PMID 21193462.
  13. Owings JT (2005). "Management of venous thromboembolism". ACS Surgery. American College of Surgeons. Archived from the original on 27 January 2012. Retrieved 16 January 2012.
  14. Martinelli I, Bucciarelli P, Mannucci PM (February 2010). "Thrombotic risk factors: basic pathophysiology". Critical Care Medicine. 38 (2 Suppl): S3–9. doi:10.1097/CCM.0b013e3181c9cbd9. PMID 20083911.
  15. Bovill EG, van der Vliet A (2011). "Venous valvular stasis-associated hypoxia and thrombosis: what is the link?". Annual Review of Physiology. 73: 527–45. doi:10.1146/annurev-physiol-012110-142305. PMID 21034220.
  16. Reitsma PH, Versteeg HH, Middeldorp S (March 2012). "Mechanistic view of risk factors for venous thromboembolism". Arteriosclerosis, Thrombosis, and Vascular Biology. 32 (3): 563–8. doi:10.1161/ATVBAHA.111.242818. PMID 22345594.
  17. Lijfering WM, Rosendaal FR, Cannegieter SC (June 2010). "Risk factors for venous thrombosis - current understanding from an epidemiological point of view". British Journal of Haematology. 149 (6): 824–33. doi:10.1111/j.1365-2141.2010.08206.x. PMID 20456358.
  18. Wong P, Baglin T (2012). "Epidemiology, risk factors and sequelae of venous thromboembolism". Phlebology. 27 Suppl 2 (suppl 2): 2–11. doi:10.1258/phleb.2012.012S31. PMID 22457300.
  19. Mantha S, Karp R, Raghavan V, Terrin N, Bauer KA, Zwicker JI (August 2012). "Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis". BMJ. 345: e4944. doi:10.1136/bmj.e4944. PMC 3413580. PMID 22872710.
  20. de Jong PG, Coppens M, Middeldorp S (August 2012). "Duration of anticoagulant therapy for venous thromboembolism: balancing benefits and harms on the long term". British Journal of Haematology. 158 (4): 433–41. doi:10.1111/j.1365-2141.2012.09196.x. PMID 22734929.
  21. Qaseem A, Chou R, Humphrey LL, Starkey M, Shekelle P (November 2011). "Venous thromboembolism prophylaxis in hospitalized patients: a clinical practice guideline from the American College of Physicians". Annals of Internal Medicine. 155 (9): 625–32. CiteSeerX doi:10.7326/0003-4819-155-9-201111010-00011. PMID 22041951.
  22. Varga EA, Kujovich JL (January 2012). "Management of inherited thrombophilia: guide for genetics professionals". Clinical Genetics. 81 (1): 7–17. doi:10.1111/j.1399-0004.2011.01746.x. PMID 21707594.
  23. Middeldorp S (2011). "Is thrombophilia testing useful?". Hematology. American Society of Hematology. Education Program. 2011 (1): 150–5. doi:10.1182/asheducation-2011.1.150. PMID 22160027.
  24. Shaheen K, Alraies MC, Alraiyes AH, Christie R (April 2012). "Factor V Leiden: how great is the risk of venous thromboembolism?". Cleveland Clinic Journal of Medicine. 79 (4): 265–72. doi:10.3949/ccjm.79a.11072. PMID 22473726.
  25. Rosendaal FR, Reitsma PH (July 2009). "Genetics of venous thrombosis". Journal of Thrombosis and Haemostasis. 7 Suppl 1 (suppl 1): 301–4. doi:10.1111/j.1538-7836.2009.03394.x. PMID 19630821.
  26. Dentali F, Sironi AP, Ageno W, Turato S, Bonfanti C, Frattini F, et al. (July 2012). "Non-O blood type is the commonest genetic risk factor for VTE: results from a meta-analysis of the literature". Seminars in Thrombosis and Hemostasis. 38 (5): 535–48. doi:10.1055/s-0032-1315758. PMID 22740183.
  27. Palareti G, Schellong S (January 2012). "Isolated distal deep vein thrombosis: what we know and what we are doing". Journal of Thrombosis and Haemostasis. 10 (1): 11–9. doi:10.1111/j.1538-7836.2011.04564.x. PMID 22082302.
  28. Jackson E, Curtis KM, Gaffield ME (March 2011). "Risk of venous thromboembolism during the postpartum period: a systematic review". Obstetrics and Gynecology. 117 (3): 691–703. doi:10.1097/AOG.0b013e31820ce2db. PMID 21343773.
  29. Turpie AG (March 2008). "Deep venous thrombosis". The Merck's Manuals Online Medical Library. Merck.
  30. Mai C, Hunt D (May 2011). "Upper-extremity deep venous thrombosis: a review". The American Journal of Medicine. 124 (5): 402–7. doi:10.1016/j.amjmed.2010.11.022. PMID 21531227.
  31. Tichelaar YI, Kluin-Nelemans HJ, Meijer K (May 2012). "Infections and inflammatory diseases as risk factors for venous thrombosis. A systematic review". Thrombosis and Haemostasis. 107 (5): 827–37. doi:10.1160/TH11-09-0611. PMID 22437808.
  32. Zöller B, Li X, Sundquist J, Sundquist K (January 2012). "Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden". Lancet. 379 (9812): 244–9. doi:10.1016/S0140-6736(11)61306-8. PMID 22119579.
  33. Baglin T (April 2012). "Inherited and acquired risk factors for venous thromboembolism". Seminars in Respiratory and Critical Care Medicine. 33 (2): 127–37. doi:10.1055/s-0032-1311791. PMID 22648484.
  34. Stephens MB (February 1997). "Deep venous thrombosis of the upper extremity". American Family Physician. 55 (2): 533–9. PMID 9054222.
  35. Brown J (2008). Oxford American Handbook of Emergency Medicine. p. 453.9. ISBN 9780199779482. Archived from the original on 8 January 2018.
  36. van Langevelde K, Flinterman LE, van Hylckama Vlieg A, Rosendaal FR, Cannegieter SC (August 2012). "Broadening the factor V Leiden paradox: pulmonary embolism and deep-vein thrombosis as 2 sides of the spectrum". Blood. 120 (5): 933–46. doi:10.1182/blood-2012-02-407551. PMID 22496157.
  37. Jenkins PV, Rawley O, Smith OP, O'Donnell JS (June 2012). "Elevated factor VIII levels and risk of venous thrombosis". British Journal of Haematology. 157 (6): 653–63. doi:10.1111/j.1365-2141.2012.09134.x. PMID 22530883.
  38. Chan WS, Spencer FA, Ginsberg JS (April 2010). "Anatomic distribution of deep vein thrombosis in pregnancy". CMAJ. 182 (7): 657–60. doi:10.1503/cmaj.091692. PMC 2855912. PMID 20351121.
  39. Saha P, Humphries J, Modarai B, Mattock K, Waltham M, Evans CE, et al. (March 2011). "Leukocytes and the natural history of deep vein thrombosis: current concepts and future directions". Arteriosclerosis, Thrombosis, and Vascular Biology. 31 (3): 506–12. doi:10.1161/ATVBAHA.110.213405. PMC 3079895. PMID 21325673.
  40. "What is deep vein thrombosis?". National Heart, Lung, and Blood Institute. 28 October 2011. Archived from the original on 25 July 2012. Retrieved 26 July 2012.
  41. Kim ES, Bartholomew JR. "Venous thromboembolism". Disease Management Project. Cleveland Clinic. Archived from the original on 23 February 2011. Retrieved 15 February 2011.
  42. López JA, Chen J (2009). "Pathophysiology of venous thrombosis". Thrombosis Research. 123 Suppl 4 (suppl 4): S30–4. doi:10.1016/S0049-3848(09)70140-9. PMID 19303501.
  43. Heil J, Miesbach W, Vogl T, Bechstein WO, Reinisch A (April 2017). "Deep Vein Thrombosis of the Upper Extremity". Deutsches Arzteblatt International. 114 (14): 244–249. doi:10.3238/arztebl.2017.0244. PMC 5415909. PMID 28446351.
  44. "DDI/9290 clinical: D-dimer, plasma". Mayo Medical Laboratories. Archived from the original on 8 October 2012. Retrieved 27 August 2012.
  45. Iorio A, Kearon C, Filippucci E, Marcucci M, Macura A, Pengo V, et al. (October 2010). "Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review". Archives of Internal Medicine. 170 (19): 1710–6. doi:10.1001/archinternmed.2010.367. PMID 20975016.
  46. Robertson L, Yeoh SE, Broderick C, Stansby G, Agarwal R (November 2018). Cochrane Vascular Group (ed.). "Effect of testing for cancer on cancer- or venous thromboembolism (VTE)-related mortality and morbidity in people with unprovoked VTE". The Cochrane Database of Systematic Reviews. 11: CD010837. doi:10.1002/14651858.CD010837.pub4. PMC 6517248. PMID 30407621.
  47. Conklin P, Soares GM, Dubel GJ, Ahn SH, Murphy TP (December 2009). "Acute deep vein thrombosis (DVT): evolving treatment strategies and endovascular therapy" (PDF). Medicine and Health, Rhode Island. 92 (12): 394–7. PMID 20066826. Archived (PDF) from the original on 6 February 2013.
  48. Rao AS, Konig G, Leers SA, Cho J, Rhee RY, Makaroun MS, Chaer RA (November 2009). "Pharmacomechanical thrombectomy for iliofemoral deep vein thrombosis: an alternative in patients with contraindications to thrombolysis". Journal of Vascular Surgery. 50 (5): 1092–8. doi:10.1016/j.jvs.2009.06.050. PMID 19782528.
  49. Lloyd NS, Douketis JD, Moinuddin I, Lim W, Crowther MA (March 2008). "Anticoagulant prophylaxis to prevent asymptomatic deep vein thrombosis in hospitalized medical patients: a systematic review and meta-analysis". Journal of Thrombosis and Haemostasis. 6 (3): 405–14. doi:10.1111/j.1538-7836.2007.02847.x. PMID 18031292.
  50. Font C, Farrús B, Vidal L, Caralt TM, Visa L, Mellado B, et al. (September 2011). "Incidental versus symptomatic venous thrombosis in cancer: a prospective observational study of 340 consecutive patients". Annals of Oncology. 22 (9): 2101–6. doi:10.1093/annonc/mdq720. PMID 21325446.
  51. Hofmann LV, Kuo WT (January 2012). "Catheter-directed thrombolysis for acute DVT". Lancet. 379 (9810): 3–4. doi:10.1016/S0140-6736(11)61875-8. PMID 22172245.
  52. Johnson SA, Stevens SM, Woller SC, Lake E, Donadini M, Cheng J, et al. (February 2010). "Risk of deep vein thrombosis following a single negative whole-leg compression ultrasound: a systematic review and meta-analysis". JAMA. 303 (5): 438–45. doi:10.1001/jama.2010.43. PMID 20124539.
  53. Welch 2010, p. 2.
  54. Galanaud JP, Bosson JL, Quéré I (September 2011). "Risk factors and early outcomes of patients with symptomatic distal vs. proximal deep-vein thrombosis". Current Opinion in Pulmonary Medicine. 17 (5): 387–91. doi:10.1097/MCP.0b013e328349a9e3. PMID 21832920.
  55. Heit JA, Mohr DN, Silverstein MD, Petterson TM, O'Fallon WM, Melton LJ (March 2000). "Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study". Archives of Internal Medicine. 160 (6): 761–8. doi:10.1001/archinte.160.6.761. PMID 10737275.
  56. Spencer FA, Emery C, Lessard D, Anderson F, Emani S, Aragam J, et al. (July 2006). "The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism". Journal of General Internal Medicine. 21 (7): 722–7. doi:10.1111/j.1525-1497.2006.00458.x. PMC 1924694. PMID 16808773.
  57. Casella IB, Bosch MA, Sabbag CR (2009). "Incidence and risk factors for bilateral deep venous thrombosis of the lower limbs". Angiology. 60 (1): 99–103. doi:10.1177/0003319708316897. PMID 18504268.
  58. Guyatt et al. 2012, p. 16S: 3.1.
  59. National Institute for Health and Clinical Excellence. Clinical guideline 144: Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing. London, 2012.
  60. Geersing GJ, Zuithoff NP, Kearon C, Anderson DR, Ten Cate-Hoek AJ, Elf JL, et al. (March 2014). "Exclusion of deep vein thrombosis using the Wells rule in clinically important subgroups: individual patient data meta-analysis". BMJ. 348: g1340. doi:10.1136/bmj.g1340. PMC 3948465. PMID 24615063.
  61. Adam SS, Key NS, Greenberg CS (March 2009). "D-dimer antigen: current concepts and future prospects". Blood. 113 (13): 2878–87. doi:10.1182/blood-2008-06-165845. PMID 19008457. Archived from the original on 15 April 2013.
  62. Guyatt et al. 2012, p. 17S: 3.4.
  63. Guyatt et al. 2012, p. 16S: 3.2.
  64. Guyatt et al. 2012, p. 16S: 3.3.
  65. Guyatt et al. 2012, p. 19S: 5.3. & 6.1.
  66. Tovey C, Wyatt S (May 2003). "Diagnosis, investigation, and management of deep vein thrombosis". BMJ. 326 (7400): 1180–4. doi:10.1136/bmj.326.7400.1180. PMC 1126050. PMID 12775619.
  67. Ozbudak O, Eroğullari I, Oğüş C, Cilli A, Türkay M, Ozdemir T (April 2006). "Doppler ultrasonography versus venography in the detection of deep vein thrombosis in patients with pulmonary embolism". Journal of Thrombosis and Thrombolysis. 21 (2): 159–62. doi:10.1007/s11239-006-5207-3. PMID 16622611.
  68. Hecht 2010, p. 47.
  69. Keeling D, Baglin T, Tait C, Watson H, Perry D, Baglin C, et al. (August 2011). "Guidelines on oral anticoagulation with warfarin - fourth edition" (PDF). British Journal of Haematology. 154 (3): 311–24. doi:10.1111/j.1365-2141.2011.08753.x. PMID 21671894. Archived from the original (PDF) on 4 May 2012. Retrieved 4 May 2012.
  70. Guyatt et al. 2012, p. 11S: 7.1.
  71. Stewart DW, Freshour JE (January 2013). "Aspirin for the prophylaxis of venous thromboembolic events in orthopedic surgery patients: a comparison of the AAOS and ACCP guidelines with review of the evidence". The Annals of Pharmacotherapy. 47 (1): 63–74. doi:10.1345/aph.1R331. PMID 23324504.
  72. Warkentin TE (November 2012). "Aspirin for dual prevention of venous and arterial thrombosis". The New England Journal of Medicine. 367 (21): 2039–41. doi:10.1056/NEJMe1211480. PMID 23121404.
  73. Li L, Zhang P, Tian JH, Yang K (December 2014). "Statins for primary prevention of venous thromboembolism". The Cochrane Database of Systematic Reviews. 12 (12): CD008203. doi:10.1002/14651858.CD008203.pub3. PMID 25518837.
  74. Simes J, Becattini C, Agnelli G, Eikelboom JW, Kirby AC, Mister R, et al. (INSPIRE Study Investigators (International Collaboration of Aspirin Trials for Recurrent Venous Thromboembolism)) (September 2014). "Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration". Circulation. 130 (13): 1062–71. doi:10.1161/circulationaha.114.008828. PMID 25156992.
  75. Lederle FA, Zylla D, MacDonald R, Wilt TJ (November 2011). "Venous thromboembolism prophylaxis in hospitalized medical patients and those with stroke: a background review for an American College of Physicians Clinical Practice Guideline". Annals of Internal Medicine. 155 (9): 602–15. doi:10.7326/0003-4819-155-9-201111010-00008. PMID 22041949.
  76. Alikhan R, Bedenis R, Cohen AT (May 2014). "Heparin for the prevention of venous thromboembolism in acutely ill medical patients (excluding stroke and myocardial infarction)". The Cochrane Database of Systematic Reviews. 5 (5): CD003747. doi:10.1002/14651858.CD003747.pub4. PMC 6491079. PMID 24804622.
  77. Kahn SR, Lim W, Dunn AS, Cushman M, Dentali F, Akl EA, et al. (February 2012). "Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines". Chest. 141 (2 Suppl): e195S–e226S. doi:10.1378/chest.11-2296. PMC 3278052. PMID 22315261.
  78. Guyatt et al. 2012, p. 10S: 2.3., 2.4., & 2.7.1.
  79. Guyatt et al. 2012, p. 10S: 2.7.2.
  80. Guyatt et al. 2012, pp. 10S–11S: 3.4.3. & 3.4.4.
  81. Guyatt et al. 2012, p. 11S: 4.2.2.
  82. Sobieraj DM, Lee S, Coleman CI, Tongbram V, Chen W, Colby J, et al. (May 2012). "Prolonged versus standard-duration venous thromboprophylaxis in major orthopedic surgery: a systematic review". Annals of Internal Medicine. 156 (10): 720–7. doi:10.7326/0003-4819-156-10-201205150-00423. PMID 22412039.
  83. Falck-Ytter Y, Francis CW, Johanson NA, Curley C, Dahl OE, Schulman S, et al. (February 2012). "Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines". Chest. 141 (2 Suppl): e278S–e325S. doi:10.1378/chest.11-2404. PMC 3278063. PMID 22315265.
  84. Gould MK, Garcia DA, Wren SM, Karanicolas PJ, Arcelus JI, Heit JA, Samama CM (February 2012). "Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines". Chest. 141 (2 Suppl): e227S–e277S. doi:10.1378/chest.11-2297. PMC 3278061. PMID 22315263.
  85. Kakkos SK, Caprini JA, Geroulakos G, Nicolaides AN, Stansby GP, Reddy DJ (October 2008). Kakkos SK (ed.). "Combined intermittent pneumatic leg compression and pharmacological prophylaxis for prevention of venous thromboembolism in high-risk patients". The Cochrane Database of Systematic Reviews (4): CD005258. doi:10.1002/14651858.CD005258.pub2. PMID 18843686.
  86. Sachdeva A, Dalton M, Lees T (November 2018). Cochrane Vascular Group (ed.). "Graduated compression stockings for prevention of deep vein thrombosis". The Cochrane Database of Systematic Reviews. 11: CD001484. doi:10.1002/14651858.CD001484.pub4. PMC 6477662. PMID 30390397.
  87. Marik PE, Plante LA (November 2008). "Venous thromboembolic disease and pregnancy". The New England Journal of Medicine. 359 (19): 2025–33. doi:10.1056/NEJMra0707993. PMID 18987370.
  88. Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO (February 2012). "VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines". Chest. 141 (2 Suppl): e691S–e736S. doi:10.1378/chest.11-2300. PMC 3278054. PMID 22315276.
  89. Guyatt et al. 2012, pp. 39S–40S: 3.0.
  90. Guyatt et al. 2012, p. 38S: 3.0.1.
  91. Guyatt et al. 2012, p. 11S: 6.1.1. & 6.1.2.
  92. Guyatt et al. 2012, p. 11S: 6.1.2. & 6.1.3.
  93. Clarke M, Hopewell S, Juszczak E, Eisinga A, Kjeldstrøm M (April 2006). Clarke MJ (ed.). "Compression stockings for preventing deep vein thrombosis in airline passengers". The Cochrane Database of Systematic Reviews (2): CD004002. doi:10.1002/14651858.CD004002.pub2. PMID 16625594.
  94. "Deep venous thrombosis". A.D.A.M. Medical Encyclopedia. PubMed Health. 19 February 2012. Archived from the original on 26 September 2012. Retrieved 2 July 2012.
  95. Cundiff DK, Manyemba J, Pezzullo JC (January 2006). Cundiff DK (ed.). "Anticoagulants versus non-steroidal anti-inflammatories or placebo for treatment of venous thromboembolism". The Cochrane Database of Systematic Reviews (1): CD003746. doi:10.1002/14651858.CD003746.pub2. PMID 16437461.
  96. Douketis J, Tosetto A, Marcucci M, Baglin T, Cushman M, Eichinger S, et al. (October 2010). "Patient-level meta-analysis: effect of measurement timing, threshold, and patient age on ability of D-dimer testing to assess recurrence risk after unprovoked venous thromboembolism". Annals of Internal Medicine. 153 (8): 523–31. doi:10.7326/0003-4819-153-8-201010190-00009. PMID 20956709.
  97. Robertson L, Kesteven P, McCaslin JE (June 2015). Cochrane Vascular Group (ed.). "Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosis". The Cochrane Database of Systematic Reviews (6): CD010956. doi:10.1002/14651858.CD010956.pub2. PMID 26123214.
  98. Guyatt et al. 2012, p. 20S: 2.4.
  99. Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, et al. (February 2012). "Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines". Chest. 141 (2 Suppl): e419S–e496S. doi:10.1378/chest.11-2301. PMC 3278049. PMID 22315268.
  100. Guyatt et al. 2012, p. 20S: 2.5.1.
  101. Guyatt et al. 2012, pp. 20S–21S: 3.1.
  102. Strijkers RH, Cate-Hoek AJ, Bukkems SF, Wittens CH (October 2011). "Management of deep vein thrombosis and prevention of post-thrombotic syndrome". BMJ. 343: d5916. doi:10.1136/bmj.d5916. PMID 22042752.
  103. Guyatt et al. 2012, p. 22S: 3.2.
  104. Middeldorp S, Prins MH, Hutten BA (August 2014). "Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism". The Cochrane Database of Systematic Reviews (8): CD001367. doi:10.1002/14651858.CD001367.pub3. PMID 25092359.
  105. Guyatt et al. 2012, p. 21S: 3.1.1.
  106. Guyatt et al. 2012, p. 21S: 3.1.2.
  107. Guyatt et al. 2012, p. 22S: 3.1.4.
  108. Guyatt et al. 2012, p. 22S:
  109. Guyatt et al. 2012, p. 22S:
  110. Guyatt et al. 2012, p. 22S:
  111. Guyatt et al. 2012, p. 22S:
  112. Guyatt et al. 2012, p. 21S: 2.7.
  113. Guyatt et al. 2012, p. 23S: 4.1.
  114. Berntsen CF, Kristiansen A, Akl EA, Sandset PM, Jacobsen EM, Guyatt G, Vandvik PO (April 2016). "Compression Stockings for Preventing the Postthrombotic Syndrome in Patients with Deep Vein Thrombosis". The American Journal of Medicine. 129 (4): 447.e1–447.e20. doi:10.1016/j.amjmed.2015.11.031. PMID 26747198.
  115. Guyatt et al. 2012, p. 21S: 2.14.
  116. American Physical Therapy Association (15 September 2014), "Five Things Physicians and Patients Should Question", Choosing Wisely: an initiative of the ABIM Foundation, American Physical Therapy Association, archived from the original on 22 September 2014, retrieved 15 September 2014, which cites
  117. Guyatt et al. 2012, p. 20S: 2.3.
  118. Young T, Tang H, Hughes R (February 2010). Young T (ed.). "Vena caval filters for the prevention of pulmonary embolism" (PDF). The Cochrane Database of Systematic Reviews (2): CD006212. doi:10.1002/14651858.CD006212.pub4. PMID 20166079.
  119. Guyatt et al. 2012, p. 21S: 2.13.1.–3.
  120. Guyatt et al. 2012, p. 21S: 2.13.
  121. Watson L, Broderick C, Armon MP (November 2016). "Thrombolysis for acute deep vein thrombosis". The Cochrane Database of Systematic Reviews. 11: CD002783. doi:10.1002/14651858.CD002783.pub4. PMC 6464997. PMID 27830895.
  122. Guyatt et al. 2012, p. 21S: 2.9 & 2.10.
  123. Guyatt et al. 2012, p. 21S: 2.11.
  124. Kahn SR (November 2009). "How I treat postthrombotic syndrome". Blood. 114 (21): 4624–31. doi:10.1182/blood-2009-07-199174. PMID 19741190. Archived from the original on 21 June 2013. Retrieved 25 June 2012.
  125. "Deep vein thrombosis/pulmonary embolism (DVT/PE)". Centers for Disease Control and Prevention. 8 June 2012. Archived from the original on 4 July 2012. Retrieved 5 July 2012.
  126. Severinsen MT, Johnsen SP, Tjønneland A, Overvad K, Dethlefsen C, Kristensen SR (August 2010). "Body height and sex-related differences in incidence of venous thromboembolism: a Danish follow-up study". European Journal of Internal Medicine. 21 (4): 268–72. doi:10.1016/j.ejim.2010.03.013. PMID 20603033.
  127. Rosendaal 2009, p. 5.
  128. Januel JM, Chen G, Ruffieux C, Quan H, Douketis JD, Crowther MA, et al. (January 2012). "Symptomatic in-hospital deep vein thrombosis and pulmonary embolism following hip and knee arthroplasty among patients receiving recommended prophylaxis: a systematic review". JAMA. 307 (3): 294–303. doi:10.1001/jama.2011.2029. PMID 22253396.
  129. Young A, Chapman O, Connor C, Poole C, Rose P, Kakkar AK (July 2012). "Thrombosis and cancer". Nature Reviews. Clinical Oncology. 9 (8): 437–49. doi:10.1038/nrclinonc.2012.106. PMID 22777060.
  130. Margaglione M, Grandone E (February 2011). "Population genetics of venous thromboembolism. A narrative review". Thrombosis and Haemostasis. 105 (2): 221–31. doi:10.1160/TH10-08-0510. PMID 20941456.
  131. "Blood types". American Red Cross. Archived from the original on 14 August 2012. Retrieved 15 August 2012.
  132. Hamasaki N (October 2012). "Unmasking Asian thrombophilia: is APC dysfunction the real culprit?". Journal of Thrombosis and Haemostasis. 10 (10): 2016–8. doi:10.1111/j.1538-7836.2012.04893.x. PMID 22905992.
  133. Goodman LR (October 2013). "In search of venous thromboembolism: the first 2913 years". AJR. American Journal of Roentgenology. 201 (4): W576–81. doi:10.2214/AJR.13.10604. PMID 24059395.
  134. Rosendaal 2009, p. 3.
  135. Bagot CN, Arya R (October 2008). "Virchow and his triad: a question of attribution". British Journal of Haematology. 143 (2): 180–90. doi:10.1111/j.1365-2141.2008.07323.x. PMID 18783400.
  136. Dalen 2003, p. 2.
  137. Dalen 2003, p. 3.
  138. Dobesh PP (August 2009). "Economic burden of venous thromboembolism in hospitalized patients". Pharmacotherapy. 29 (8): 943–53. doi:10.1592/phco.29.8.943. PMID 19637948.
  139. Ruppert A, Steinle T, Lees M (2011). "Economic burden of venous thromboembolism: a systematic review". Journal of Medical Economics. 14 (1): 65–74. doi:10.3111/13696998.2010.546465. PMID 21222564.
  140. Grosse SD (January 2012). "Incidence-based cost estimates require population-based incidence data. A critique of Mahan et al" (PDF). Thrombosis and Haemostasis. 107 (1): 192–3, author reply 194–5. doi:10.1160/TH11-09-0666. PMID 22159589. Archived (PDF) from the original on 8 August 2017.
  141. Mahan CE, Holdsworth MT, Welch SM, Borrego M, Spyropoulos AC (September 2011). "Deep-vein thrombosis: a United States cost model for a preventable and costly adverse event". Thrombosis and Haemostasis. 106 (3): 405–15. doi:10.1160/TH11-02-0132. PMID 21833446.
  142. Mahan CE, Holdsworth MT, Welch SM, et al. (2012). "Long-term attack rates, as compared with incidence rates, may provide improved cost-estimates in venous thromboembolism. A reply to S. D. Grosse". Thromb Haemost. 107 (1): 194–5. doi:10.1160/TH11-11-0802.
  143. Becattini C, Agnelli G, Schenone A, Eichinger S, Bucherini E, Silingardi M, et al. (May 2012). "Aspirin for preventing the recurrence of venous thromboembolism". The New England Journal of Medicine. 366 (21): 1959–67. doi:10.1056/NEJMoa1114238. hdl:10447/75301. PMID 22621626.
  144. Brighton TA, Eikelboom JW, Mann K, Mister R, Gallus A, Ockelford P, et al. (November 2012). "Low-dose aspirin for preventing recurrent venous thromboembolism" (PDF). The New England Journal of Medicine. 367 (21): 1979–87. doi:10.1056/NEJMoa1210384. PMID 23121403.
Cited literature
External resources

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.